Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALLTogether protocol for newly diagnosed acute lymphoblastic leukemia in patients aged 0-45 years
NL-OMON59593Phase 3Recruiting
- Sponsor
- Karolinska University Hospital
- Start
- Jul 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate, inotuzumab ozogamicin, tioguanine and blinatumomab in acute lymphoblastic leukemia (ALL), B lymphoblastic leukemia/lymphoma (B-ALL/LBL) and Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL) (7 arms), sponsored by Karolinska University Hospital. Primary endpoints: Event-free survival, Disease-free survival and 1 more. Started Jul 2020; status: recruiting.
02
Drugs
methotrexateinotuzumab ozogamicintioguanineblinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)B lymphoblastic leukemia/lymphoma (B-ALL/LBL)Precursor T-cell lymphoblastic leukemia/lymphoma (T-LBL/ALL)
Beyond the preview
Go deeper on NL-OMON59593.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59593.